Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparison of outcomes in pediatric patients with acute leukemia undergoing allogeneic HLA-haploidentical hematopoietic stem cell transplantation (HSCT) after in vitro a/b T- and CD19-cell depletion or In Vivo administration of post-transplant cyclophosphamide: An EBMT pediatric working party study

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMichael MaschanRRRawad RihaniIGIbrahim Ghemlas

Discussion

Loading...

Member takes

Overview

Observational analysis shows lower relapse incidence in children with acute leukemia receiving hematopoietic stem cell transplantation using a/b T- and CD19-cell depletion, highlighting reduced graft-

Key Points

  • Cox model analysis indicated significant differences in relapse incidence and graft-versus-host disease between the two transplant approaches.
  • The study involved 1071 children with acute leukemia who underwent hematopoietic stem cell transplantation between 2010 and 2022.
  • In vitro a/b T- and CD19-cell depleted transplant showed lower rates of acute and chronic graft-versus-host disease compared to post-transplant cyclophosphamide.
  • Both transplant platforms are suitable for children needing urgent hematopoietic stem cell transplantation with outcomes favoring the a/b-TCD approach.

Cite This Study

Maschan et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e18fhttps://doi.org/10.1182/blood-2025-515
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combination of post-transplant cyclophosphamide and anti-thymocyte globulin for haploidentical stem cell transplantation in pediatric patients with acute leukemia2026
  2. 2Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT2025
  3. 3Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation2025
  4. 4Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation2025
  5. 5Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT2025